BeiGene gains further approvals for Brukinsa in Latin America

Sino-American biotech BeiGene (HKEX: 06160) claims significant progress in its efforts to unlock global opportunities for its Brukinsa (zanubrutinib) with recent regulatory approvals in six Latin American countries.

Specifically, these are in: Argentina for relapsed/refractory (r/r) mantle cell lymphoma (MCL); Chile for r/r marginal zone lymphoma (MZL) and Waldenström’s macroglobulinemia (WM); Ecuador for r/r MZL and WM; El Salvador for r/r MCL, r/r MZL, and WM; Mexico for r/r MCL; and Paraguay for r/r MCL.

“It has only been one year since the first approval for Brukinsa in Latin America and these approvals, including the most recent in Argentina, demonstrate our drive to accomplish our mission and broaden access to innovative medicines,” said Eduardo Molinari, senior director of new market development in Latin America at BeiGene, adding: “I look forward to collaborating with our partner, Adium, on commercialization activities to provide this important treatment option to people living with MCL, MZL, and WM in Latin America.”